Home > Maligne hematologie > Lymfoïde ziekten > Non-Hodgkin lymfomen (NHL) > High-Grade B-Cell Lymphoma (HGBCL) > ZUMA23

ZUMA23

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23) https://clinicaltrials.gov/study/NCT05605899

Deze print is 24 uur geldig na het aanmaken. Aangemaakt op: 20-6-2025, 3:45